L-Tryptophan Supplementation in Parkinson's Disease

References

• Barbeau A. The pathogenesis of Parkinson's disease: A new hypothesis. Canadian Medical Association Journal 1962; 87: 802–807
   PubMedGoogle Scholar
• Birkmayer W., Neumayer E. Die Behandlung der DOPA-psychoses mit L-tryptophan. Der Nervenarzt 1972; 43: 76–78
   Google Scholar
• Chase T. N. 5-hydroxytryptophan in Parkinsonism. Lancet 1970; 2: 1029–1030
   PubMed Web of Science ®Google Scholar
• Chase T. N., Ng L. K. Y., Watanabe A. M. Parkinson's disease: Modification of 5-hydroxytryptophan. Neurology 1972; 22: 479–484
   PubMed Web of Science ®Google Scholar
• Coppen A., Metcalfe M., Carroll J. D., Morris J. G. L. Levodopa and L-tryptophan therapy in Parkinsonism. Lancet 1972; 1: 654–658
   Google Scholar
• Curzon G. Therapeutic effect of levodopa in relation to pretreatment amine metabolite concentration in cerebrospinal fluid. Advances in Neurology, D. B. Calne. Raven Press, New York 1973; Vol. 3: 165–172
   Google Scholar
• Dray A. Serotonin in the basal-ganglia: Functions and interactions with other neuronal pathways. Journal of Physiology (Paris) 1981; 77: 393–403
   PubMedGoogle Scholar
• Everett G. M., Borcherding J. W. L-dopa: Effect on concentrations of dopamine, norepinephrine, and serotonin in brains of mice. Science 1970; 168: 849–850
   PubMed Web of Science ®Google Scholar
• Fahn S., Snider S. R., Prasad L. N., Lane E., Makadon H. Normalization of brain serotonin by L-tryptophan in levodopa-treated rats. Neurology 1975; 25: 861–865
   PubMed Web of Science ®Google Scholar
• Fahn S., Libsch L. R., Cutler R. W. Monoamines in the human neostriatum: Topographic distribution in normal and in Parkinson's disease and their role in akinesia, rigidity, chorea, and tremor. Journal of the Neurological Sciences 1971; 14: 427–455
   PubMed Web of Science ®Google Scholar
• Gehlen W., Muller J. Zur Therapie der dopa Psychosen mit L-tryptophan. Deutsche Medizinische Wochenschrift 1974; 99: 457–463
   Google Scholar
• Gershanik O. S., Heikkila R. E., Duvoisin R. C. The role of serotonin neurons in the action of L-dopa in an animal model of Parkinsonism. Neurology 1979; 29: 553
   Web of Science ®Google Scholar
• Goldstein M., Frenkel R. Inhibition of serotonin by dopa and other catechols. Nature (New Biology) 1971; 233: 179
   PubMedGoogle Scholar
• Gumpert E. J. W., Sharpe D. M., Curzon G. Amine metabolites in cerebrospinal fluid in Parkinson's disease and the response to L-dopa. Journal of the Neurological Sciences 1973; 19: 1–12
   PubMed Web of Science ®Google Scholar
• Jequier E., Dufresne J. J. Biochemical investigations in patients with Parkinson's disease treated with L-dopa. Neurology 1972; 22: 231–237
   PubMedGoogle Scholar
• Klawans H. L., Goetz C. G., Bergen D. Levodopa-induced myoclonus. Archives of Neurology 1975; 32: 331–334
   Google Scholar
• Lehmann J. Tryptophan malabsorption in levodopa-treated Parkinsonian patients. Acta Medica Scandinavica 1973; 194: 181–189
   PubMedGoogle Scholar
• Lehmann J. Levodopa and depression in Parkinsonism. Lancet 1971; 1: 140
   PubMedGoogle Scholar
• Lloyd K. G. Neurochemistry of the substantia nigra (SN) in Parkinson's disease. International Society for Neurochemistry. Copenhagen. 1977; 252
   Google Scholar
• Lloyd K. G., Hornykiewicz O. Dopamine and other monoamines in the basal-ganglia: Relation to brain dysfunction. Frontier in neurology and neuroscience research, P. Seeman, G. M. Brown. Neuroscience Institute, University of Toronto, Toronto 1974; 26–35
   Google Scholar
• Mayeux R., Stern Y., Cote L., Williams J. B. W. Altered serotonin metabolism in depressed patients with Parkinson's disease. Neurology 1984; 34: 642–646
   PubMed Web of Science ®Google Scholar
• Mayeux R., Stern Y., Williams J. B. W., Cote L., Frantz A., Dyrenfurth I. Clinical and biochemical features of depression in Parkinson's disease. American Journal of Psychiatry 1986; 143: 756–759
   PubMed Web of Science ®Google Scholar
• Meerwaldt J. D. Treatment of hypokinetic rigid syndrome with fluvoxamine maleate. Lancet 1986; 2: 977–978
   Google Scholar
• Mena I., Court J., Fuenzalida S., Papavasiiou P. S., Cotzias G. C. Modification of chronic manganese poisoning: Treatment with L-dopa or 5-OH tryptophane. New England Journal of Medicine 1970; 282: 5–10
   PubMed Web of Science ®Google Scholar
• Miller E. M., Nieburg H. A. L-tryptophan in the treatment of levodopa-induced psychiatric disorders. Diseases of the Nervous System 1974; 35: 2–23
   Google Scholar
• Moir A. T. B. Interaction in the cerebral metabolism of the biogenic amines: Effects of intravenous infusion of L-tryptophan on the metabolism of dopamine and 5-hydroxyindoles in brain and cerebrospinal fluid. British Journal of Pharmacology 1971; 43: 715–723
   PubMedGoogle Scholar
• Nausieda P. A., Tanner C. M., Klawans H. L. Serotonergically active agents in levodopa-induced psychiatric toxicity reactions. Advances in Neurology, S. Fahn, D. B. Calne, I. Shoulson. Raven Press, New York 1983; Vol. 37: 23–32
   Google Scholar
• Ng L. K. Y., Chase T. N., Colburn R. W., Kopin I. J. L-dopa induced release of cerebral monoamines. Science 1970; 170: 76–77
   PubMed Web of Science ®Google Scholar
• Nutt J. G. On-Off phenomenon: Relation to levodopa pharmakokinetics and pharmacodynamics. Annals of Neurology 1987; 22: 535–540
   PubMed Web of Science ®Google Scholar
• Reisine T. D., Fields J. Z., Yamamura H. I., Bird E. D., Spokes E., Schreiner P. S., Enna S. J. Neurotransmitter receptor alterations in Parkinson's disease. Life Sciences 1977; 21: 335–344
   PubMed Web of Science ®Google Scholar
• Sandyk R. Serotonergic mechanisms in levodopa-induced “On-Off” and sleep disorders in Parkinson's disease. International Journal of Neuroscience., (in press)
   Google Scholar
• Sano I., Taniguchi K. L-5-hydroxytryptophan(1–5-HTP) therapie des morbus Parkinson. Munschner Medizinische Wochenschrift 1972; 114: 1717–1719
   PubMedGoogle Scholar